<code id='936F039B08'></code><style id='936F039B08'></style>
    • <acronym id='936F039B08'></acronym>
      <center id='936F039B08'><center id='936F039B08'><tfoot id='936F039B08'></tfoot></center><abbr id='936F039B08'><dir id='936F039B08'><tfoot id='936F039B08'></tfoot><noframes id='936F039B08'>

    • <optgroup id='936F039B08'><strike id='936F039B08'><sup id='936F039B08'></sup></strike><code id='936F039B08'></code></optgroup>
        1. <b id='936F039B08'><label id='936F039B08'><select id='936F039B08'><dt id='936F039B08'><span id='936F039B08'></span></dt></select></label></b><u id='936F039B08'></u>
          <i id='936F039B08'><strike id='936F039B08'><tt id='936F039B08'><pre id='936F039B08'></pre></tt></strike></i>

          Home / fashion / fashion

          fashion


          fashion

          author:fashion    Page View:515
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe

          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 

          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

          advertisement

          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In